Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786474 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,884
- Enrollment target
NCT00786474 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 1,884 participants.
The verdict
NCT00786474, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,884 participants
- Enrollment target
Study Summary
Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much bleeding during and after the surgery or procedure. Some doctors prescribe a different blood thinner, one that works more quickly and wears off more quickly, to bridge the gap between starting and stopping warfarin. However, this short-term treatment is expensive, may increase the risk of bleeding, and has not been proven effective. This study will determine whether a bridging blood thinner called dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or a procedure.
Interventions
- DRUG Placebo
- DRUG Dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,884 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00786474
The ClinicalTrials.gov registry entry for NCT00786474 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,884 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00786474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00786474 about?
NCT00786474 is a clinical study titled "Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)". Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much bleeding during and after the surgery or procedure. Some doctors prescribe a...
What is the current status of trial NCT00786474?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,884 participants. The study started on 2009-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00786474?
The interventions under investigation include: Placebo (DRUG), Dalteparin (DRUG).
Who is sponsoring clinical trial NCT00786474?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.